The clinical course of Crohn’s disease in a Danish population-based inception cohort with more than 50 years of follow-up, 1962-2017

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Background: Few population-based studies have investigated the long-term prognosis of Crohn's disease (CD). Aim: To determine the long-term natural disease course of CD with regard to surgery, cancer and mortality in a population-based cohort followed for more than 50 years. Methods: All patients diagnosed with CD from 1962 to 1987 in Copenhagen County, Denmark were included in a population-based cohort. Information about surgeries, cancers and mortality was collected from patient files from 1962 to 1987 and from the Danish National Patient Registry, Cancer Registry, and from the Register of Causes of Death, 1987-2017. Patients were matched with individuals from the general population. Results: A total of 373 patients were followed for a median of 33 years (range: 0-56 years). The cumulative probability of surgery 10, 20, 30, 40 and 50 years after diagnosis was 62% (CI 95%: 57%-67%), 71% (CI 95%: 66%-75%), 72% (CI 95%: 67%-76%), 74% (CI 95%: 69%-79%) and 74% (CI 95%: 69%-79%), respectively. A total of 142 patients (54%) were operated upon at least twice: 69 (26%) needing two surgeries and 73 (28%) needing three or more. Patients with CD were found to be at increased risk of intestinal (small bowel, rectum and anus) and extra-intestinal (respiratory organs and skin) cancer. All-cause mortality among CD patients was higher than among controls (RR: 1.22, CI 95%: 1.04-1.43), whereas mortality due to gastrointestinal cancer was not. Conclusion: After 50 years of follow-up, 75% CD patients had undergone surgery, with most needing repeat surgery. The risk of intestinal and extra-intestinal cancers, as well as mortality, was higher among CD patients than the background population.

OriginalsprogEngelsk
TidsskriftAlimentary Pharmacology and Therapeutics
Vol/bind55
Udgave nummer1
Sider (fra-til)73-82
ISSN0269-2813
DOI
StatusUdgivet - 2022

Bibliografisk note

Funding Information:
This study was funded in part by Colitis Crohn Foreningen by an unrestricted grant.

Funding Information:
JB has received consulting or lecture fees from AbbVie, Janssen‐Cilag, Celgene, Takeda, Tillotts Pharma, Merck Sharp & Dohme, Pfizer, Samsung Bioepis and Bristol Myers Squibb, and research funds from AbbVie, Takeda, Tillots Pharma, Merck Sharp & Dohme, Bristol Myers Squibb and the Novo Nordisk Foundation. SL: none. EL: has received consulting or lecture fees from Takeda, Tillotts Pharma, Merck Sharp & Dome, Abbvie and Ferring Pharmaceuticals. PM has received consulting or lecture fees from AbbVie, Calpro, Falk Pharma, Ferring Pharmaceuticals, Janssen‐Cilag, Merck Sharp & Dohme and Tillotts Pharma, and research funds from AbbVie, Calpro, Coloplast, Ferring Pharmaceuticals, Janssen‐Cilag, Merck Sharp and Dohme, Pharmaforce and Tillotts Pharma. Declaration of personal interests:

Publisher Copyright:
© 2021 John Wiley & Sons Ltd

ID: 280727306